Versant Capital Management Inc Has $43,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Versant Capital Management Inc lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 626 shares of the biopharmaceutical company’s stock after selling 171 shares during the period. Versant Capital Management Inc’s holdings in Gilead Sciences were worth $43,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $29,000. Palisade Asset Management LLC bought a new stake in Gilead Sciences during the first quarter worth approximately $29,000. Sachetta LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $30,000. Rakuten Securities Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $33,000. Finally, Gladius Capital Management LP bought a new stake in Gilead Sciences during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.64 during midday trading on Tuesday, reaching $74.19. The company’s stock had a trading volume of 5,310,668 shares, compared to its average volume of 7,401,109. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a market capitalization of $92.43 billion, a P/E ratio of 207.86, a P/E/G ratio of 3.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The business’s fifty day simple moving average is $68.98 and its 200-day simple moving average is $70.58.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research reports. Barclays reduced their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Oppenheimer reissued an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Maxim Group reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald reduced their price objective on Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating for the company in a research report on Monday, July 22nd. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $81.81.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.